Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1-pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Wincell Research
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This autologous dendritic cell vaccine is developed by Wincell Research in collaboration with Osaka University. The therapy involves isolating a patient's monocytes, which are then matured into dendritic cells and pulsed with Wilms' Tumor 1 (WT1) antigens. Once re-administered to the patient, these primed dendritic cells present WT1 epitopes to T cells, inducing a potent cytotoxic T-lymphocyte (CTL) response against WT1-expressing malignant cells and cancer stem cells. It is primarily indicated for the prevention of cancer recurrence and the treatment of various WT1-positive solid tumors and hematological malignancies. The vaccine has received approval from the Thai FDA.
- Brand names
- WT1-DC Cancer VaccineWT-1-DC Cancer VaccineWT 1-DC Cancer Vaccine
- Other names
- WT1-pulsed dendritic cell vaccineWT-1-pulsed dendritic cell vaccineWT 1-pulsed dendritic cell vaccineWT1-DC vaccineWT-1-DC vaccineWT 1-DC vaccine
02
Targets
WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on WT1-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1-pulsed dendritic cell vaccine.